Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Clinical trial NCT02605993 · COMPLETED
Trial details
- NCT number
- NCT02605993
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-04
- Primary completion
- 2017-02-23
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.